A nomogram for overall survival of second primary cancers following upper-tract urothelial carcinoma: a SEER population-based study.

With improving prognosis in upper-tract urothelial carcinoma (UTUC), an increasing number of second primary malignancies (SPMs) are being identified. However, there is limited research on SPMs following UTUC. This study aims to evaluate the risk of SPMs in UTUC patients and create a nomogram to predict their survival rates.

Utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database, we assessed the risk of SPMs among UTUC patients. Additionally, we developed and validated an overall survival (OS) nomogram for SPM patients post-UTUC diagnosis.

The prevalence of SPMs among UTUC patients was 30.23%, with solid tumors being the most prevalent type of second malignancy, constituting 95.30% of all SPMs. The overall risk of SPMs was significantly elevated across all subgroups. Univariate and multivariate Cox regression analyses identified age, race, gender, UTUC SEER historic stage, surgery, SPM site, histologic type, grade, and SEER historic stage as independent prognostic factors for SPM OS. Subsequently, we developed a nomogram for predicting SPM OS. The C-index for the training and validation sets were 0.72 [95% confidence interval (CI): 0.70-0.74] and 0.71 (95% CI: 0.67-0.75), respectively. The area under the curve (AUC) demonstrated good performance of our model in predicting the 3-year (0.73 and 0.737) and 5-year (0.723 and 0.733) OS of SPMs in both sets.

This study represents the first comprehensive analysis of SPM incidence in UTUC patients and introduces a nomogram for predicting SPM prognosis.

Translational cancer research. 2024 Aug 12 [Epub]

Xi Zhang, Weikang Chen, Chunming Li, Xiaojie Wan, Peifeng Xu, Tao Zhang

Department of Gynecology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, China., Department of Reproductive Endocrinology, Zhejiang University School of Medicine Women's Hospital, Hangzhou, China., Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Hangzhou, China.